New cocktail of cancer drugs targets brain metastases in melanoma patients
NCT ID NCT03175432
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether combining bevacizumab (Avastin) with atezolizumab (Tecentriq), with or without cobimetinib (Cotellic), can shrink or control melanoma that has spread to the brain. The study enrolls 29 adults with untreated brain metastases who are not taking steroids or are on a low dose. Researchers will measure how well the tumors respond inside the brain and track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab (Avastin), atezolizumab (Tecentriq), and cobimetinib (Cotellic)
- What this could lead to
- If successful, this could point toward a new treatment option for melanoma that has spread to the brain, potentially shrinking or controlling brain tumors.
- What could go wrong
- This is a small, early-phase trial (Phase 2) with only 29 participants, so results may not apply to everyone. The drug combination can cause serious side effects like bleeding, immune reactions, and organ inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF V600 WILD TYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma